Novuspharma shows impressive data for Pixantrone in the CHOP-variant regimen.

Zdroj: PharmaWatch: Cancer. December 2003, Vol. 2 Issue 12, p14-15. 2p.
Databáze: Business Source Ultimate
Externí odkaz: